



Robert Greene Sterne  
Edward J. Kessler  
Jorge A. Goldstein  
David K.S. Commwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michelle A. Cimballa  
Michael B. Ray  
Robert E. Solzoh  
Eric K. Steffe  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Alcorn  
Robert C. Millonig  
Lawrence B. Bugalsky  
Donald J. Featherstone  
Michael V. Messinger  
Judith U. Kim  
Timothy J. Shea, Jr.

Patrick E. Garrett  
Jeffrey I. Hevey  
Heidi L. Kraus  
Crystal D. Sayles  
Edward W. Yee  
Albert L. Ferro  
Donald R. Banowitz  
Peter A. Jackman  
Molly A. McCall  
Teresa U. Medler  
Jeffrey S. Weaver  
Kendrick P. Patterson  
Vincent L. Capuano  
Albert J. Fasulo II  
Eldora Ellison Floyd  
W. Russell Swindell  
Thomas C. Flala  
Brian J. Del Buono  
Virgil Lee Beason  
Reginald D. Lucas

Kimberly N. Reddick  
Theodore A. Wood  
Elizabeth J. Haanes  
Bruce E. Chalker  
Joseph S. Ostroff  
Frank R. Cottingham  
Christine M. Ulfner  
Rae Lynn Prensaman  
Jane Shershenovich  
Lawrence J. Carroll  
George S. Bardmesser

Senior Counsel  
Samuel L. Fox  
Kenneth C. Bass III

Registered Patent Agents  
Karen R. Markowicz  
Andrea J. Kamage

Nancy J. Leith  
Joseph M. Conrad  
Ann E. Surmon  
Helene C. Carls  
Gabry L. Longworth  
Matthew J. Dowd  
Aaron L. Schwartz  
Angelique G. Uy  
Boris A. Matvenko  
Mary B. Tung  
Katrina Y. Pei  
Bryan L. Skelton  
Jason D. Eisenberg

\*Admitted only in Maryland  
\*Admitted only in Virginia  
\*Admitted only in Texas

#4  
KAY  
6-4-02  
Attachment

TECH CENTER 1600 2600

JUN 04 2002

RECEIVED

May 31, 2002

WRITER'S DIRECT NUMBER:  
(202) 371-2615  
INTERNET ADDRESS:  
FRANKC@SKGF.COM

Art Unit 1632

Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Utility Patent Application  
Appl. No. 10/052,817; Filed: January 23, 2002  
For: **Alpha-2-Macroglobulin Therapies and Drug Screening Methods for  
Alzheimer's Disease**  
Inventors: Tanzi *et al.*  
Our Ref: 0609.4460005/JAG/FRC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement;
2. Listing of the cited documents on Form PTO-1449 (30 sheets);
3. A copy of each of the one-hundred and one (101) cited documents on Form PTO-1449; and
4. Return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents  
May 31, 2002  
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Frank R. Cottingham  
Attorney for Applicants  
Registration No. 50,437

FRC/pcd  
Enclosures

SKGF\_DC1:18622.1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

JUN 0 4 2002

RECEIVED

In re application of:

Tanzi *et al.*

Appl. No. 10/052,817

Filed: January 23, 2002

For: **Alpha-2-Macroglobulin Therapies  
and Drug Screening Methods for  
Alzheimer's Disease**

Confirmation No. 4182

Art Unit: 1632

Examiner: *To be assigned*

Atty. Docket: 0609.4460005/JAG/FRC

### Information Disclosure Statement

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each of these documents is provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

The Examiner is referred to the following related, co-pending patent application:

U.S. Patent Application No. 60/337,434, filed November 9, 2001, inventors Becker *et al.*, submitted herewith as Document **AT30**.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not

be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

Document AS30 is the International Search Report for International Application No. PCT/US00/02412, which corresponds to the captioned U.S. Application.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).


It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

This Information Disclosure Statement is being filed more than three months after the filing date, but before the mailing date of a first Office Action on the merits. No statement or fee is required.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Frank R. Cottingham  
Attorney for Applicants  
Registration No. 50,437

Date: 5/31/02

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600



RECEIVED

JUN 04 2002

TECH CENTER 1600/2900  
Page 1 of 30

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRCAPPLICATION NO.  
10/052,817APPLICANT  
Tanzi et al.FILING DATE  
01/23/2002GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	4,683,195	07/28/1987	Mullis et al.	435	6	02/07/1986
	AB1	5,830,670	11/03/1998	de la Monte et al.	435	7.2	05/30/1995
	AC1	5,948,634	09/07/1999	de la Monte et al.	435	69.1	11/14/1994
	AD1	5,948,888	09/07/1999	de la Monte et al.	530	350	05/30/1995
	AE1	6,071,705	06/06/2000	Wands et al.	435	7.1	06/06/1995
	AF1	6,156,311	12/05/2000	Strickland et al.	424	130.1	07/26/1996
	AG1						
	AH1						
	AI1						
	AJ1						
	AK1						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1	WO 91/03557	03/21/1991	WIPO			Yes No
	AM1	WO 92/03474	03/05/1992	WIPO			Yes No
	AN1	WO 96/39834	12/19/1996	WIPO			Yes No
	AO1	WO 97/04794	02/13/1997	WIPO			Yes No
	AP1	WO 99/11824	03/11/1999	WIPO			Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>1</u>	"Freely Associating," Nat. Genet. 22:1-2, Nature America, Inc. (May 1999).
	AS	<u>1</u>	Alvarez, V. et al., Association between an $\alpha 2$ Macroglobulin DNA Polymorphism and Late-Onset Alzheimer's Disease," <i>Biochem. Biophys. Res. Commun.</i> 264:48-50, Academic Press, Inc. (October 1999).
	AT	<u>1</u>	Andersen, G.R. et al., "Low Resolution X-Ray Structure of Human Methylamine-treated $\alpha 2$ -Macroglobulin," <i>J. Biol. Chem.</i> 270:25133-25141, American Society for Biochemistry and Molecular Biology, Inc. (1995).
EXAMINER			DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

JUN 04 2002

Page 2 of 30

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRCTECH CENTER 1600/2900  
10/052,817APPLICANT  
Tanzi et al.FILING DATE  
01/23/2002GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>2</u>	Barrett, A.J. et al., "The Electrophoretically 'Slow' and 'Fast' Forms of the $\alpha$ 2-Macroglobulin Molecule," <i>Biochem. J.</i> 181:401-418, Portland Press, Ltd. (1979).
	AS	<u>2</u>	Bauer, J. et al., "Interleukin-6 and $\alpha$ 2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <i>FEBS Lett.</i> 285:111-114, Elsevier Science Publisher B.V. (1991).
	AT	<u>2</u>	Blacker, D. et al., "Correspondence," <i>Nat. Genet.</i> 22:21-22, Nature America, Inc. (May 1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

JUN 04 2002

TECH CENTER 1600/2900



FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/ERCAPPLICATION NO.  
10/052,817APPLICANT  
Tanzi et al.FILING DATE  
01/23/2002GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	3	Blacker, D. et al., "Alpha-2 macroglobulin is genetically associated with Alzheimer disease," <i>Nat. Genet.</i> 19:357-360, Nature America, Inc. (August 1998).
	AS	3	Blennow, K. et al., "No association between the $\alpha$ 2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression," <i>J. Neural. Transm.</i> 107:1065-1079, Springer-Verlag (August 2000).
	AT	3	Boado, R.J., "Antisense drug delivery through the blood-brain barrier," <i>Adv. Drug Deliv. Rev.</i> 15:73-107, Elsevier Science Publishers B.V. (1995).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

JUN 04 2002

TECH CENTER 1600/2900

Page 4 of 30

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRCAPPLICATION NO.  
10/052,817APPLICANT  
Tanzi et al.FILING DATE  
01/23/2002GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	4	Boado, R.J. et al., "Drug delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," <i>J. Pharm. Sci.</i> 87:1308-1315, American Pharmaceutical Association (November 1998).
	AS	4	Borth, W., "α2-Macroglobulin, a multifunctional binding protein with targeting characteristics," <i>FASEB J.</i> 6:3345-3353, FASEB (1992).
	AT	4	Bowen, M.E. and Gettins, P.G.W., "Bait Region Involvement in the Dimer-Dimer Interface of Human α2-Macroglobulin and in Mediating Gross Conformational Change," <i>J. Biol. Chem.</i> 273:1825-1831, American Society for Biochemistry and Molecular Biology, Inc. (January 1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.





RECEIVED

JUN 04 2002

TECH CENTER 1600/2900  
Page 1 of 30

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRCAPPLICATION NO.  
10/052,817APPLICANT  
Tanzi et al.FILING DATE  
01/23/2002GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>5</u>	Bretondiere, J-P. et al., "Structure of native $\alpha$ 2-macroglobulin and its transformation to the protease bound form," <i>Proc. Natl. Acad. Sci. USA</i> 85:1437-1441, National Academy Press (1988).
	AS	<u>5</u>	Businaro, R. et al., "Synthesis and secretion of $\alpha$ 2-macroglobulin by human glioma established cell lines," <i>Exp. Brain Res.</i> 88:213-218, Springer-Verlag (1992).
	AT	<u>5</u>	Cavus, I. et al., "Inhibition of Long-Term Potentiation Development in Rat Hippocampal Slice by $\alpha$ 2-Macroglobulin, an Acute-Phase Protein in the Brain," <i>J. Neurosci. Res.</i> 43:282-288, Wiley-Liss, Inc. (February 1996).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

JUN 04 2002

TECH CENTER 1600/2900  
Page 6 of 30

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRCAPPLICATION NO.  
10/052,817APPLICANT  
Tanzi et al.FILING DATE  
01/23/2002GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>6</u>	Chen, L. et al., "Apolipoprotein E promoter and $\alpha$ 2-Macroglobulin polymorphisms are not genetically associated with Chinese late onset Alzheimer's Disease," <i>Neurosci. Lett.</i> 269:173-177, Elsevier Science Ireland, Ltd. (July 1999).
	AS	<u>6</u>	Crawford, F. et al., "The alpha-2 macroglobulin gene is not associated with Alzheimer's disease in a case-control sample," <i>Neurosci. Lett.</i> 270:133-136, Elsevier Science Ireland, Ltd. (August 1999).
	AT	<u>6</u>	Dodel, R.C. et al., " $\alpha$ 2-Macroglobulin and the risk of Alzheimer's disease," <i>Neurology</i> 54:438-442, Lippincott, Williams & Wilkins (January 2000).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

JUN 04 2002

TECH CENTER 1600/2900 of 30

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRCAPPLICATION NO.  
10/052,817APPLICANT  
Tanzi et al.FILING DATE  
01/23/2002GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	1	Dow, D.J. et al., "α2-macroglobulin polymorphism and Alzheimer disease risk in the UK," <i>Nat. Genet.</i> 22:16-17, Nature America, Inc. (May 1999).
	AS	1	Du, Y. et al., "α2-Macroglobulin Attenuates β-Amyloid Peptide 1-40 Fibril Formation and Associated Neurotoxicity of Cultured Fetal Rat Cortical Neurons," <i>J. Neurochem.</i> 70:1182-1188, Lippincott-Raven Publishers (March 1998).
	AT	1	Du, Y. et al., "α2-Macroglobulin as a β-Amyloid Peptide-Binding Plasma Protein," <i>J. Neurochem.</i> 69:299-305, Lippincott-Raven Publishers (July 1997).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

JUN 04 2002

TECH CENTER 1600/2980 of 30

FORM PTO-1

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRCAPPLICATION NO.  
10/052,817APPLICANT  
Tanzi *et al.*FILING DATE  
01/23/2002GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	8	Fakler, B. <i>et al.</i> , "Short Antisense Oligonucleotide-mediated Inhibition Is Strongly Dependent on Oligo Length and Concentration but Almost Independent of Location of the Target Sequence," <i>J. Biol. Chem.</i> 269:16187-16194, American Society for Biochemistry and Molecular Biology, Inc. (1994).
	AS	8	Feldman, S.R. <i>et al.</i> , "Model of $\alpha$ 2-Macroglobulin structure and function," <i>Proc. Natl. Acad. Sci. USA</i> 82:5700-5704, National Academy Press (1985).
	AT	8	Gauderman, W.J. <i>et al.</i> , "Family-Based Association Studies," <i>J. Natl. Cancer Inst. Monogr.</i> 26:31-37, Oxford University Press (December 1999).


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

# RECEIVED

JUN 04 2002



TECH CENTER 1001/2900  
Page 1 of 30

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRC

APPLICATION NO.  
10/052,817

APPLICANT  
Tanzi et al.

FILING DATE  
01/23/2002

GROUP  
1632

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

### OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	9	Gliemann, J., "Receptors of the Low Density Lipoprotein (LDL) Receptor Family in Man. Multiple Functions of the Large Family Members via Interaction with Complex Ligands," <i>Biol. Chem.</i> 379:951-964, Walter de Gruyter and Company (August/September 1998).
AS	9	Hampe, J. et al., "Mapping Genes for Polygenic Disorders: Considerations for Study Design in the Complex Trait of Inflammatory Bowel Disease," <i>Hum. Hered.</i> 50:91-101, S. Karger AG (March-April 2000).
AT	9	Hardy, J., "Amyloid, the presenilins and Alzheimer's disease," <i>Trends Neurosci.</i> 20:154-159, Elsevier Science, Ltd. (April 1997).

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

JUN 04 2002

Page 18 of 90

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRCTECH CENTER 1000/2909  
APPL. NO. 10/052,817APPLICANT  
Tanzi et al.FILING DATE  
01/23/2002GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>10</u>	Hollenbach, E. et al., "Confirmation of an association between a polymorphism in the exon 3 of the low-density lipoprotein receptor-related protein gene and Alzheimer's disease," <i>Neurology</i> 50:1905-1907, Lippincott-Raven Publishers (June 1998).
	AS	<u>10</u>	Horvath, S. and Laird, N.M., "A Discordant-Sibship Test for Disequilibrium and Linkage: No Need for Parental Data," <i>Am. J. Hum. Genet.</i> 63:1886-1897, University of Chicago Press (December 1998).
	AT	<u>10</u>	Hu, C-J. et al., "No association of alpha-2 macroglobulin gene five-nucleotide deletion with AD in Taiwan Chinese," <i>Neurology</i> 53:642-643, Lippincott, Williams & Wilkins (August 1999).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

JUN 04 2002

Page 11 of 30

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRCTECHNICAL CENTER 1600/2900  
10/052,817APPLICANT  
Tanzi et al.FILING DATE  
01/23/2002GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>11</u>	Hughes, S.R. et al., "α2-macroglobulin associates with β-amyloid peptide and prevents fibril formation," <i>Proc. Natl. Acad. Sci. USA</i> 95:3275-3280, National Academy Press (March 1998).
	AS	<u>11</u>	Jinnah, H.A. and Friedmann, T., "Gene therapy and the brain," <i>Br. Med. Bull.</i> 51:138-148, Oxford University Press (1995).
	AT	<u>11</u>	Justus, C.W.E. et al., "Quantification of free α2-macroglobulin and α2-macroglobulin-protease complexes by a novel ELISA system based on streptococcal α2-macroglobulin receptors," <i>J. Immunol. Methods</i> 126:103-108, Elsevier Science Publishers B.V. (1990).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

JUN 04 2002

Page 12 of 30

FORM PTO-144

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRCTECH CENTER 1600/2900  
APPLICATION NO.  
10/052,817APPLICANT  
Tanzi et al.FILING DATE  
01/23/2002GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>12</u>	Kan, C-C. et al., "Nucleotide sequence of cDNA encoding human $\alpha$ 2-macroglobulin and assignment of the chromosomal locus," <i>Proc. Natl. Acad. Sci. USA</i> 82:2282-2286, National Academy Press (1985).
	AS	<u>12</u>	Kang, D.E. et al., "Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease," <i>Neurology</i> 49:56-61, Lippincott-Raven Publishers (July 1997).
	AT	<u>12</u>	Kolodziej, S.J. et al., "Three-Dimensional Structure of the Human Plasmin $\alpha$ 2-Macroglobulin Complex," <i>J. Struct. Biol.</i> 123:124-133, Academic Press, Inc. (October 1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.





JUN 04 2002

TECH CENTER 1600/2900

Page 13 of 30

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRCAPPLICATION NO.  
10/052,817APPLICANT  
Tanzi et al.FILING DATE  
01/23/2002GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>13</u>	Korovaitseva, G.I. et al., "Alpha-2 macroglobulin gene in early- and late-onset Alzheimer disease," <i>Neurosci. Lett.</i> 271:129-131, Elsevier Science Ireland, Ltd. (August 1999).
	AS	<u>13</u>	Koster, M.N. et al., "The $\alpha$ 2-macroglobulin gene in AD. A population-based study and meta-analysis," <i>Neurology</i> 55:678-684, Lipincott, Williams & Wilkins (September 2000).
	AT	<u>13</u>	Kounnas, M.Z. et al., "LDL Receptor-Related Protein, a Multifunctional ApoE Receptor, Binds Secreted $\beta$ -Amyloid Precursor Protein and Mediates Its Degradation," <i>Cell</i> 82:331-340, Cell Press (1995).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

JUN 04 2002

TECH CENTER 1600/2900  
Page 14 of 30

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRC

APPLICATION NO.  
10/052,817

APPLICANT  
Tanzi et al.

FILING DATE  
01/23/2002

GROUP  
1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	14	Kounnas, M.Z. et al., "The Cellular Internalization and Degradation of Hepatic Lipase Is Mediated by Low Density Lipoprotein Receptor-related Protein and Requires Cell Surface Proteoglycans," <i>J. Biol. Chem.</i> 270:9307-9312, American Society for Biochemistry and Molecular Biology, Inc. (1995).
	AS	14	Kounnas, M.Z. et al., "LDL Receptor-Related Protein (LPR) Binds Secreted $\beta$ -Amyloid Precursor Protein and Mediates Its Degradation," <i>Mol. Biol. Cell</i> 6:327A, No. 1901, American Society for Cell Biology (1995).
	AT	14	Kovacs, D.M. et al., "Alpha-2-Macroglobulin-2 Allele Associated with Alzheimer's Disease: RNA and Protein Products," A Keystone Symposium on Aging: Genetic and Environmental Influences on Life Span. Tamarron, Colorado (February 2-7, 1999).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

JUN 04 2002

TECH CENTER 1600/2900  
Page 15 of 30

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRCAPPLICATION NO.  
10/052,817APPLICANT  
Tanzi et al.FILING DATE  
01/23/2002GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>15</u>	Kovacs, D.M., "α2-Macroglobulin in late-onset Alzheimer's disease," <i>Exper. Gerontol.</i> 35:473-479, Elsevier Science, Inc. (July 2000).
	AS	<u>15</u>	Kovács, T. et al., "Alpha-2-macroglobulin intronic polymorphism is not associated with autopsy-confirmed late-onset Alzheimer's disease," <i>Neurosci. Lett.</i> 273:61-63, Elsevier Science Ireland, Ltd. (September 1999).
	AT	<u>15</u>	Krüger, R. et al., "Genetic analysis of the α2-macroglobulin gene in early- and late-onset Parkinson's disease," <i>NeuroReport</i> 11:2439-2442, Lippincott, Williams & Wilkens (August 2000).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

JUN 04 2002

TECH CENTER 1600/2900  
Page 16 of 30

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/ERCAPPLICATION NO.  
10/052,817APPLICANT  
Tanzi et al.FILING DATE  
01/23/2002GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>16</u>	Lake, S.L. et al., "Family-Based Tests of Association in the Presence of Linkage," <i>Am. J. Hum. Genet.</i> 67:1515-1525, University of Chicago Press (December 2000).
	AS	<u>16</u>	Le Corre, S.M. et al., "Critical Issues in the Antisense Inhibition of Brain Gene Expression <i>In Vivo</i> : Experiences Targeting the 5-HT <sub>1A</sub> Receptor," <i>Neurochem. Int.</i> 31:349-362, Elsevier Science, Ltd. (September 1997).
	AT	<u>16</u>	Liao, A. et al., "Genetic association of an $\alpha$ 2-macroglobulin (VA1100011e) polymorphism and Alzheimer's disease," <i>Hum. Mol. Genet.</i> 7:1953-1956, Oxford University Press (November 1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

JUN 04 2002

TECH CENTER 1600/2900 of 30  
APPLICATION NO.  
10/052,817

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRCAPPLICANT  
Tanzi et al.FILING DATE  
01/23/2002GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>17</u>	Lopes, M.B.S. et al., "Expression of $\alpha$ 2-macroglobulin receptor/low density lipoprotein receptor-related protein is increased in reactive and neoplastic glial cells," <i>FEBS Lett.</i> 338:301-305, Elsevier Science Publisher B.V. (1994).
	AS	<u>17</u>	Lorent, K. et al., "Expression in mouse embryos and in adult mouse brain of three members of the amyloid precursor protein family, of the alpha-2-macroglobulin receptor/low density lipoprotein receptor-related protein and of its ligands apolipoprotein E, lipoprotein lipase, alpha-2-macroglobulin and the 40,000 molecular weight receptor-associated protein," <i>Neuroscience</i> 65:1009-1025, Elsevier Science, Ltd. (1995).
	AT	<u>17</u>	Marynen, P. et al., "A monoclonal antibody to a neo-antigen on $\alpha$ 2-macroglobulin complexes inhibits receptor-mediated endocytosis," <i>J. Immunol.</i> 127:1782-1786, American Association of Immunologists (1981).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

JUN 04 2002

TECH CENTER 1600/2900  
Page 18 of 30

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRCAPPLICATION NO.  
10/052,817APPLICANT  
Tanzi et al.FILING DATE  
01/23/2002GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>18</u>	Marynen, P. et al., "A genetic polymorphism in a functional domain of human pregnancy zone protein: the bait region," <i>FEBS Lett.</i> 262:349-352, Elsevier Science Publishers B.V. (1990).
	AS	<u>18</u>	Matthijs, G. and Marynen, P., "A deletion polymorphism in the human alpha-2-macroglobulin (A2M) gene," <i>Nucleic Acids Res.</i> 19:5102, Oxford University Press (1991).
	AT	<u>18</u>	Misra, U.K. and Pizzo, S.V., "Binding of Receptor-recognized Forms of $\alpha$ 2-Macroglobulin to the $\alpha$ 2-Macroglobulin Signaling Receptor Activates Phosphatidylinositol 3-Kinase," <i>J. Biol. Chem.</i> 273:13399-13402, American Society for Biochemistry and Molecular Biology, Inc. (May 1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

JUN 04 2002

TECH CENTER 1600/2800 9 of 30

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRCAPPLICATION NO.  
10/052,817APPLICANT  
Tanzi *et al.*FILING DATE  
01/23/2002GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	19	Mori, T. <i>et al.</i> , " $\alpha$ 2-Macroglobulin is an astroglia-derived neurite-promoting factor for cultured neurons from rat central nervous system," <i>Brain Res.</i> 527:55-61, Elsevier Science Publisher B.V. (1990).
	AS	19	Myllykangas, L. <i>et al.</i> , "Genetic Association of $\alpha$ 2-Macroglobulin with Alzheimer's Disease in a Finnish Elderly Population," <i>Ann. Neurol.</i> 46:382-390, Lippincott, Williams & Wilkins (September 1999).
	AT	19	Narita, M. <i>et al.</i> , " $\alpha$ 2-Macroglobulin Complexes with and Mediates the Endocytosis of $\beta$ -Amyloid Peptide via Cell Surface Low-Density Lipoprotein Receptor-Related Protein," <i>J. Neurochem.</i> 69:1904-1911, Lippincott-Raven Publishers (November 1997).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

JUN 04 2002



TECH CENTER 1000/2000 30

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRCAPPLICATION NO.  
10/052,817APPLICANT  
Tanzi et al.FILING DATE  
01/23/2002GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	20	Nielsen, K.L. et al., "Identification of Residues in $\alpha$ -Macroglobulins Important for Binding to the $\alpha$ 2-Macroglobulin Receptor/Low Density Lipoprotein Receptor-related Protein," <i>J. Biol. Chem.</i> 271:12909-12912, American Society for Biochemistry and Molecular Biology, Inc. (May 1996).
	AS	20	Poller, W. et al., "Cloning of the human $\alpha$ 2-macroglobulin gene and detection of mutations in two functional domains: the bait region and the thiolester site," <i>Hum. Genet.</i> 88:313-319, Springer-Verlag (1992).
	AT	20	Poller, W. et al., "Sequence polymorphism in the human alpha-2-macroglobulin (A2M) gene," <i>Nucleic Acids Res.</i> 19:198, Oxford University Press (1991).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



JUN 04 2002

TECH CENTER 1600/2900  
Page 21 of 30

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRCAPPLICATION NO.  
10/052,817APPLICANT  
Tanzi et al.FILING DATE  
01/23/2002GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>21</u>	Qiu, W.Q. et al., "Degradation of Amyloid $\beta$ -Protein by a Serine Protease- $\alpha$ 2-Macroglobulin Complex," <i>J. Biol. Chem.</i> 271:8443-8451, American Society for Biochemistry and Molecular Cell Biology, Inc. (April 1996).
	AS	<u>21</u>	Rebeck, G.W. et al., "Multiple, Diverse Senile Plaque-associated Proteins Are Ligands of an Apolipoprotein E Receptor, the $\alpha$ 2-Macroglobulin Receptor/Low Density-Lipoprotein Receptor-related Protein," <i>Ann. Neurol.</i> 37:211-217, Lippincott, Williams & Wilkins (1995).
	AT	<u>21</u>	Reeck, G.R. et al., "'Homology' in Proteins and Nucleic Acids: A Terminology Muddle and a Way out of It," <i>Cell</i> 50:667, Cell Press (1987).

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

JUN 04 2002

TECH CENTER 1600/2900 30

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 609.4460005/JAG/FRC	APPLICATION NO. 10/052,817
		APPLICANT Fanzi et al.	
		FILING DATE 01/23/2002	GROUP 1632

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>22</u>	Rogaeva, E.A. et al., "An $\alpha$ 2-macroglobulin insertion-deletion polymorphism in Alzheimer disease," <i>Nat. Genet.</i> 22:19-21, Nature America, Inc. (May 1999).
	AS	<u>22</u>	Romas, S.N. et al., "The deletion polymorphism and Val1000Ile in $\alpha$ 2-macroglobulin and Alzheimer disease in Caribbean Hispanics," <i>Neurosci. Lett.</i> 279:133-136, Elsevier Science Ireland, Ltd. (February 2000).
	AT	<u>22</u>	Rudrasingham, V. et al., " $\alpha$ 2-macroglobulin gene and Alzheimer disease," <i>Nat. Genet.</i> 22:17-19, Nature America, Inc. (May 1999).


EXAMINER	DATE CONSIDERED
----------	-----------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

# RECEIVED

JUN 04 2002

TECH CENTER 1600/2900 Page 23 of 30



FORM PTO-1449  
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRC

APPLICATION NO.  
10/052,817

APPLICANT  
Tanzi et al.

FILING DATE  
01/23/2002

GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	23	Selkoe, D.J. et al., "Cell biology of the amyloid $\beta$ -protein precursor and the mechanism of Alzheimer's disease," <i>Annu. Rev. Cell Biol.</i> 10:373-403 (1994).
AS	23	Shibata, N. et al., "Genetic association between alpha-2 macroglobulin and Japanese sporadic Alzheimer's disease," <i>Neurosci. Lett.</i> 271:132-134, Elsevier Science Ireland, Ltd. (August 1999).
AT	23	Singleton, A.B. et al., " $\alpha$ 2-Macroglobulin polymorphisms in Alzheimer's disease and dementia with Lewy bodies," <i>NeuroReport</i> 10:1507-1510, Lippincott, Williams & Wilkens (May 1999).

EXAMINER


DATE CONSIDERED

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

JUN 04 2002

TECH CENTER 1600/2900 30

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 0609.4460005/JAG/FRC	APPLICATION NO. 10/052,817
		APPLICANT Tanzi et al.	
		FILING DATE 01/23/2002	GROUP 1632

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
AR	24	Sodeyama, N. et al., "α2-Macroglobulin polymorphism is not associated with AD or AD-type neuropathology in the Japanese," <i>Neurology</i> 54:443-446, Lippincott, Williams & Wilkins (January 2000).	
AS	24	Soto, C. et al., "Inhibition of Alzheimer's Amyloidosis by Peptides That Prevent β-Sheet Conformation," <i>Biochem. Biophys. Res. Commun.</i> 226:672-680, Academic Press, Inc. (September 1996).	
AT	24	Soto, C. et al., "β-Sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy," <i>Nat. Med.</i> 4:822-826, Nature America, Inc. (July 1998).	

EXAMINER	DATE CONSIDERED
----------	-----------------


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

JUN 04 2002

TECH CENTER 1600/2900  
Page 25 of 30

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRCAPPLICATION NO.  
10/052,817APPLICANT  
Tanzi et al.FILING DATE  
01/23/2002GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	25	Sottrup-Jensen, L. et al., "Primary Structure of Human $\alpha$ 2-Macroglobulin," J. Biol. Chem. 259:8318-8327, American Society of Biological Chemists, Inc. (1984).
	AS	25	Stratagene, 1988 Catalog, "Gene Characterization Kits," La Jolla, CA (February 1997).
	AT	25	Strauss, S. et al., "Detection of Interleukin-6 and $\alpha$ 2-Macroglobulin Immunoreactivity in Cortex and Hippocampus of Alzheimer's Disease Patients," Lab. Invest. 66:223-230, Lippincott, Williams & Wilkins (1992).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

JUN 04 2002

TECH CENTER 1600/2900  
Page 26 of 30

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 0609.4460005/JAG/FRC	APPLICATION NO. 10/052,817
	APPLICANT Tanzi et al.	
	FILING DATE 01/23/2002	GROUP 1632

PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>26</u>	Strickland, D.K. et al., "Sequence Identity between the $\alpha$ 2-Macroglobulin Receptor and Low Density Lipoprotein Receptor-related Protein Suggests That This Molecule Is a Multifunctional Receptor," <i>J. Biol. Chem.</i> 265:17401-17404, American Society for Biochemistry and Molecular Biology, Inc. (1990).
	AS	<u>26</u>	Strickland, D.K. et al., "Primary Structure of $\alpha$ 2-Macroglobulin Receptor-associated Protein. Human Homologue of a Heymann Nephritis Antigen," <i>J. Biol. Chem.</i> 266:13364-13369, American Society for Biochemistry and Molecular Biology, Inc. (1991).
	AT	<u>26</u>	Tanzi, R.E. et al., "Amyloid $\beta$ protein Gene: cDNA, mRNA Distribution, and Genetic Linkage Near the Alzheimer Locus," <i>Science</i> 235:880-884, American Association for the Advancement of Science (1987).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

JUN 04 2002

Page 27 of 30

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT


 ATTY. DOCKET NO.  
0609.4460005/JAG/FRC

 APPLICANT  
Tanzi et al.

 FILING DATE  
01/23/2002

 APPLICATION NO.  
10/052,817

 GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	27	Tanzi, R.E., "A genetic dichotomy model for the inheritance of Alzheimer's disease and common age-related disorders," <i>J. Clin. Invest.</i> 104:1175-1179, American Society for Clinical Investigation (November 1999).
	AS	27	Tirode, F. et al., "A Conditionally Expressed Third Partner Stabilizes or Prevents the Formation of a Transcriptional Activator in a Three-hybrid System," <i>J. Biol. Chem.</i> 272:22995-22999, American Society for Biochemistry and Molecular Biology, Inc. (September 1997).
	AT	27	Tooyama, I. et al., "Immunohistochemical Study of $\alpha 2$ Macroglobulin Receptor in Alzheimer and Control Postmortem Human Brain," <i>Mol. Chem. Neuropathol.</i> 18:153-160, Humana Press, Inc. (1993).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.


RECEIVED

JUN 04 2002

Page 28 of 30

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRCAPPLICANT  
Tanzi et al.FILING DATE  
01/23/2002GROUP  
1632TECH CENTER 1600/2900  
10/052,817

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	28	Van Gool, D. et al., "α2-Macroglobulin Expression in Neuritic-Type Plaques in Patients with Alzheimer's Disease," <i>Neurobiol. Aging</i> 14:233-237, Pergamon Press, Ltd. (1993).
AS	28	Van Leuven, F. et al., "The Receptor-binding Domain of Human α2-Macroglobulin. Isolation after Limited Proteolysis with a Bacterial Proteinase," <i>J. Biol. Chem.</i> 261:11369-11373, American Society of Biological Chemists, Inc. (1986).
AT	28	Verpillat, P. et al., "α2-Macroglobulin Gene and Alzheimer's Disease: Confirmation of Association by Haplotypes Analyses," <i>Ann. Neurol.</i> 48:400-402, Lippincott, Williams & Wilkins (September 2000).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.




RECEIVED

JUN 04 2002

TECH CENTER 1000/2900 30

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/FRCAPPLICATION NO.  
10/052,817APPLICANT  
Ganzi et al.FILING DATE  
01/23/2002GROUP  
1632

## PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>29</u>	Wavrant-DeVrière, F. et al., "Association between the low density lipoprotein receptor-related protein (LRP) and Alzheimer's disease," <i>Neurosci. Lett.</i> 227:68-70, Elsevier Science Ireland, Ltd. (May 1997).
	AS	<u>29</u>	Wavrant-DeVrière, F. et al., "No association between the alpha-2 macroglobulin 11000V polymorphism and Alzheimer's disease," <i>Neurosci. Lett.</i> 262:137-139, Elsevier Science Ireland, Ltd. (March 1999).
	AT	<u>29</u>	Zhang, Z. et al., "Inhibition of $\alpha$ 2-macroglobulin/proteinase-mediated degradation of amyloid $\beta$ peptide by apolipoprotein E and $\alpha$ 1-antichymotrypsin," <i>Int. J. Exp. Clin. Invest.</i> 3:156-161, Parthenon Publishing (September 1996).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.


RECEIVED

JUN 04 2002

TECH CENTER 1600/2900  
Page 30 of 30

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
0609.4460005/JAG/ERCAPPLICATION NO.  
10/052,817APPLICANT  
Manzi et al.FILING DATE  
01/23/2002GROUP  
1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL2						Yes No
	AM2						Yes No
	AN2						Yes No
	AO2						Yes No
	AP2						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	30	Zill, P. et al., "Polymorphisms in the $\alpha$ 2-macroglobulin gene in psychogeriatric patients," <i>Neurosci. Lett.</i> 294:69-72, Elsevier Science Ireland, Ltd. (November 2000).
AS	30	International Search Report for International Application No. PCT/US00/02412, mailed July 6, 2000.
AT	30	Copy of co-pending U.S. Application No. 60/337,434, Becker et al., filed November 9, 2001.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.